Biocon Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of Biocon rose 472.91% to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4123.00 crore in the quarter ended December 2025 as against Rs 3773.00 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 373.85, up 0.42% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.04% on the day, quoting at 25738.7. The Sensex is at 83674.2, down 0.08%. Biocon Ltd has dropped around 4.47% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has dropped around 2.45% in last one month and is currently quoting at 22200.25, down 0.07% on the day. The volume in the stock stood at 7.52 lakh shares today, compared to the daily average of 33.42 lakh shares in last one month.

The benchmark February futures contract for the stock is quoting at Rs 375.75, up 0.51% on the day. Biocon Ltd is down 4.2% in last one year as compared to a 8.62% gain in NIFTY and a 1.45% gain in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Biocon Ltd is up for a third straight session today. The stock is quoting at Rs 383.95, up 1.31% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 25755.6. The Sensex is at 83702.57, up 0.38%. Biocon Ltd has slipped around 0.56% in last one month.

Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 1.33% in last one month and is currently quoting at 22505.4, down 0.86% on the day. The volume in the stock stood at 17.89 lakh shares today, compared to the daily average of 26.3 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 384.45, up 1.33% on the day. Biocon Ltd is down 2.48% in last one year as compared to a 11% jump in NIFTY and a 1.13% jump in the Nifty Pharma index.

The PE of the stock is 0 based on TTM earnings ending September 25.

Powered by Capital Market - Live News

Biocon announced the successful completion of a Qualified Institutions Placement (QIP), raising Rs 4,150 crore (~USD 460 million) through the issuance of 112,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per equity share (including a premium of Rs 363.35 per equity share).

The QIP, which opened on 12 January 2026, and closed on 14 January 2026, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in Biocon's growth prospects.

The proceeds from the QIP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics, including repayment of debt availed in this regard. Biocon recently announced that its Board of Directors had approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon Biologics a wholly owned subsidiary of the Company.

Powered by Capital Market - Live News